A Study of Laquinimod Eye-drops in Healthy Participants

Status Completed

Clinical Trial Summary

This is a Phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

Clinical Trial Description

Laquinimod administered as an oral capsule formulation has previously been studied in neurodegenerative and autoimmune diseases. The clinical side effect profile of orally administered laquinimod is well-characterized based on this previous experience. This trial will establish a safe and tolerated dose of laquinimod when administered as an eye-drop formulation following single ascending dose (SAD) and multiple ascending dose (MAD) administrations. There are four planned groups in the SAD-part of the study which will enroll 28 participants, if all dose levels are explored. The subsequent MAD-part of the study will enroll another 28 participants. ;

Study Design

Related Conditions & MeSH terms

Eye Diseases

Clinical Trial Details

NCT number	NCT05187403
Study type	Interventional
Source	Active Biotech AB
Contact
Status	Completed
Phase	Phase 1
Start date	December 9, 2021
Completion date	January 19, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Completed	`NCT02811692` - Study for Collection of Aflibercept Data in Routine Practice
Recruiting	`NCT06045299` - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia	Phase 3
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT04799704` - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting	`NCT05876689` - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting	`NCT04123626` - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene	Phase 1/Phase 2
Recruiting	`NCT04150432` - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children	N/A
Not yet recruiting	`NCT05550740` - Repeated Low-Level Red-Light Therapy for Shortening Axial Length	N/A
Completed	`NCT02332343` - Sparing of the Fovea in Geographic Atrophy Progression	N/A
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Terminated	`NCT01225146` - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)	Phase 1
Completed	`NCT00333203` - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study	Phase 3
Not yet recruiting	`NCT05565547` - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting	`NCT05158699` - Effectiveness of Periocular Drug Injection in CATaract Surgery	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Completed	`NCT05211089` - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting	`NCT06070467` - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
Completed	`NCT02946879` - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)